March 2-4, 2020



is a R&D driving pharmaceutical company focus on niche specialty generics and intermediates, with high tech barrier, such as multi-chiral and fermentation

Our manufacturing sites have been approved by FDA EDQM PMDA KFDA and CFDA.

We have full pipeline in ADC cytotoxic payloads, its starting material, and linkers:

  • Maytansinoids: Ansamitocin P3, DM1 DM4 DM1-SMCC
  • Auristatins: MMAE MMAF and intermediates, Vc-MMAE
  • Calicheamicin

Contact if you have any interests.